INT48390

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 1994
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 10
Total Number 10
Disease Relevance 7.39
Pain Relevance 3.28

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (CSF2) extracellular region (CSF2)
Anatomy Link Frequency
choroid plexus 4
blood 2
plasma 2
neurons 2
PGE2 2
CSF2 (Homo sapiens)
Pain Link Frequency Relevance Heat
lidocaine 5 99.88 Very High Very High Very High
cva 86 99.32 Very High Very High Very High
cytokine 35 95.92 Very High Very High Very High
local anesthetic 2 92.24 High High
Potency 6 90.60 High High
dexamethasone 43 89.92 High High
cINOD 13 89.84 High High
aspirin 6 83.00 Quite High
headache 14 80.16 Quite High
Pain 6 77.40 Quite High
Disease Link Frequency Relevance Heat
Cv General 4 Under Development 18 99.32 Very High Very High Very High
Disease 254 99.30 Very High Very High Very High
Creutzfeldt Jakob Disease 20 98.88 Very High Very High Very High
Pseudotumor Cerebri 54 98.20 Very High Very High Very High
Intracranial Hypertension 8 97.92 Very High Very High Very High
Muscular Spasm 6 96.72 Very High Very High Very High
Respiratory Failure 2 96.28 Very High Very High Very High
Vascular Dementia 9 95.96 Very High Very High Very High
Frontotemporal Dementia 4 95.64 Very High Very High Very High
Infection 2 94.96 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Second, phosphodiesterase inhibitors 3-isobutyl-1-methylxanthine (IBMX) and Ro-201724 (both of which elevate cAMP levels) decreased GM-CSF release, in the presence of PGE2.
Negative_regulation (decreased) of Localization (release) of GM-CSF in PGE2
1) Confidence 0.51 Published 2005 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15680249 Disease Relevance 0.12 Pain Relevance 0.90
Its carbonic anhydrase inhibition decreases the secretion of CSF by the choroid plexus.
Negative_regulation (decreases) of Localization (secretion) of CSF in choroid plexus
2) Confidence 0.49 Published 2010 Journal Annals of Indian Academy of Neurology Section Body Doc Link PMC2859586 Disease Relevance 0.88 Pain Relevance 0.46
Likewise, fluticasone was the strongest steroid in inhibiting release of GM-CSF (IC25 8.4x10(-11) M), followed by budesonide (IC25 2x10(-9) M), beclomethasone dipropionate (IC25 13x10(-8) M), and nedocromil sodium (IC25 >10(-5) M).
Negative_regulation (inhibiting) of Localization (release) of GM-CSF
3) Confidence 0.37 Published 1997 Journal Eur. Respir. J. Section Abstract Doc Link 9230235 Disease Relevance 0.21 Pain Relevance 0.29
Upon diagnosis of all features of IIH, patients were initially assigned to Group 1: medical treatment consisting of carbonic anhydrase inhibitors (e.g., acetazolamide) that decrease CSF secretion by the choroid plexus. [5] Acetazolamide [1–2 g/day] was used for all patients but its dosage was reduced in patients who were not able to tolerate the side effects (i.e., nausea, vomiting, sedation, and metabolic acidosis).
Negative_regulation (decrease) of Localization (secretion) of CSF in choroid plexus associated with vomiting, cva, sleep disorders and acid base imbalance
4) Confidence 0.36 Published 2010 Journal Annals of Indian Academy of Neurology Section Body Doc Link PMC2859586 Disease Relevance 1.18 Pain Relevance 0.16
However, the findings for AD subjects were not conclusive, and lower levels of CSF ?
Neg (not) Negative_regulation (lower) of Localization (levels) of CSF associated with disease
5) Confidence 0.31 Published 2010 Journal International Journal of Alzheimer's Disease Section Body Doc Link PMC2965495 Disease Relevance 1.80 Pain Relevance 0
Detection of a proteinase inhibitor, 14-3-3 protein released from damaged neurons into CSF fortifies the diagnosis [3,4].
Negative_regulation (inhibitor) of Localization (released) of CSF in neurons
6) Confidence 0.27 Published 2008 Journal Cases J Section Body Doc Link PMC2547099 Disease Relevance 1.58 Pain Relevance 0.03
In addition, blood contamination may prevent accurate evaluation of the CSF ?
Spec (may) Negative_regulation (prevent) of Localization (evaluation) of CSF in blood
7) Confidence 0.25 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC3000080 Disease Relevance 0.75 Pain Relevance 0
From our findings, we can say that CNP concentration in the CSF was high in the acute phase and decreased gradually after SAH, whereas CNP in the plasma did not change.
Negative_regulation (decreased) of Localization (concentration) of CSF in plasma associated with cva
8) Confidence 0.20 Published 2001 Journal Crit Care Section Body Doc Link PMC29055 Disease Relevance 0.64 Pain Relevance 0.20
Lidocaine also abolished the priming effect of rhG-CSF for enhanced release of O2- in neutrophils and inhibited rhG-CSF-induced CD11b upregulation and LAM-1 downregulation on neutrophils in a dose-dependent manner.
Negative_regulation (abolished) of Localization (release) of rhG-CSF in neutrophils associated with lidocaine
9) Confidence 0.15 Published 1994 Journal Exp. Hematol. Section Abstract Doc Link 7513653 Disease Relevance 0.24 Pain Relevance 0.69
BOL-303242-X significantly inhibited G-CSF, IL-6, IL-8, and MCP-1 release from HConFs at doses of 1–100 nM in a dose-dependent manner (Figure 1).
Negative_regulation (inhibited) of Localization (release) of G-CSF
10) Confidence 0.06 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2790480 Disease Relevance 0 Pain Relevance 0.55

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox